Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin secretion and inhibit glucagon se